Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient (male or female) ≥12 years of age~* ECOG (Eastern Cooperative Oncology Group) performance status ≤1~* Must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or appropriate.~* Patients must be willing and able to undergo study required biopsies.~* Presence of at least one measurable lesion according to RECIST v1.1.~* Documented MAPK pathway alteration~Exclusion Criteria:~* Prior treatment with ERK inhibitors.~* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.~* Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.~* Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study.~* Patients with malignant disease other than that being treated in the study.~* Clinically significant cardiac disease.~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escalation (Type: EXPERIMENTAL): None
- Expansion Group 1 (Type: EXPERIMENTAL): None
- Expansion Group 2 (Type: EXPERIMENTAL): None
- Expansion Group 3 (Type: EXPERIMENTAL): None
- Expansion Group 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).